Earlier this week, I argued that clinicians studying avatar therapy for schizophrenia should ask families what changed. Families are often the first to notice when a loved one stops arguing with the voices at dinner, or sleeps through the night again.
Now a new study has answered the question every promising treatment eventually faces: Can we afford it? Researchers across sites in Hungary, Poland, and Spain published an economic evaluation of virtual reality avatar therapy for people whose auditory hallucinations hadn’t responded to standard treatment. In avatar therapy, a person builds a digital face and voice for the voice that torments them, then faces it with a therapist and practices talking back.
Participants spent 12 weeks on a waiting list with usual care, followed by 12 weeks of avatar therapy. According to the study summary, symptoms barely moved during the wait. During therapy, they dropped by 6.4 points on a standard hallucination scale, with the largest change in how distressing the voices felt. Participants also became less convinced that their voices were all-powerful or malicious.
The added cost came to about €316 per patient from the health system’s point of view, and €267 from society’s. That works out to roughly €28,780 and €24,270 per quality-adjusted life year, within the range European systems generally accept.
Real physician voices, twice a week
Free, and one click to unsubscribe.
That is good news, and I want to be careful with it. The study included 62 people. It compared each person with themselves rather than with a randomized control group, and it followed them for weeks, not years. The gain in quality-adjusted life years was small: 0.011. The authors say plainly that larger randomized trials are needed. I agree.
But I want to point to one line in the results that deserves more attention than it will get. The cost dropped once researchers took the wider societal view, because people lost less productivity while their symptoms improved. In other words, when you widen the lens beyond the clinic, the treatment looks better.
So widen it one more step.
I’m a mother of an adult daughter who lives with schizophrenia. I know what treatment-resistant voices cost a household, and almost none of it shows up on a hospital invoice. It’s the days of work a parent misses. It’s a sibling driving across the state at midnight. It’s the 2 a.m. phone calls, and the vigilance that never quite switches off.
Those costs are real and measurable, and economic evaluations often leave them out. Whether they were counted here, the summary doesn’t say. If they weren’t, a treatment that reduces how distressed and frightened a person feels is likely undervalued, because some of that distress spills onto the people around them.
That gives the next round of research three clear asks.
- First, count caregiver time: If the societal analysis can capture a patient’s productivity, it can capture the hours a mother spends managing a crisis.
- Second, add family-reported outcomes: Ask the people who live with the patient whether home life changed. A 6-point drop on a rating scale is a number. “She came back to the dinner table” is the outcome families are waiting for.
- Third, plan for access now: The authors wrote this study to inform European reimbursement decisions. American families need someone here asking the same question: Which health systems will train therapists, and which payers will cover it?
Too many promising tools for serious mental illness stall in the gap between “it works in a trial” and “it’s available where I live.” Avatar therapy has now shown it can help, and that it doesn’t cost a fortune. The next step is making sure the evidence counts everyone it touches, including the families who have been carrying the cost of the voices all along.
Nicole Drapeau Gillen is a mother, advocate, and author who translates the fast-moving landscape of technology in serious mental illness (SMI) care into guidance families and clinicians can use. Thrust into caregiving for a loved one with SMI, with no direction on how to help, she turned that experience into a mission, writing two books and building an ongoing effort to bring families and clinicians into the conversation.
Her first book, Schizophrenia and Related Disorders: A Handbook for Caregivers, is a reference for every stage of caregiving, endorsed by Dr. E. Fuller Torrey as a must-read for SMI caregivers. Her second, Connected Care: A Practical Guide to Technology for Serious Mental Illness, maps apps, artificial intelligence tools, telepsychiatry, and brain-based treatments for a field moving faster than anyone can track. Dr. Akira Sawa, director of the Johns Hopkins Schizophrenia Center, has said the book “directly addresses” significant gaps.
She shares updates on LinkedIn and Facebook.
Your KevinMD author page is one of the top results for your name. Turn it into a premium profile, publish in 1 to 3 days, and get a guaranteed podcast slot.

